Global OC/LEP Market (2024 Edition): Analysis by Type (Combination Contraceptives Pills, Progestin-only Pills), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

Global OC/LEP Market (2024 Edition): Analysis by Type (Combination Contraceptives Pills, Progestin-only Pills), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

Executive Summary

Azoth Analytics has released a research report titled “Global OC/LEP Market (2024 Edition)” which provides a Combination Contraceptives Pills analysis of the Global OC/LEP industry in terms of market segmentation By Type (Combination Contraceptives Pills, Progestin-only Pills), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the OC/LEP Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Netherlands, China, Japan, India). The Global OC/LEP market showcased growth at a CAGR of 4.59% during 2020-2023. The market was valued at USD 16.30 Billion in 2023 which is expected to reach USD 22.95 Billion in 2030.

The global OC/LEP market has been experiencing significant growth. This expansion is driven by increasing awareness of family planning, rising demand for effective contraceptive methods, and greater accessibility to healthcare services. Low estrogen pills are favoured due to their reduced risk of side effects compared to traditional higher-dose pills, making them a preferred choice for many women seeking hormonal birth control options

There is an increasing awareness about reproductive health and contraceptive options among women globally. Educational campaigns by governments and non-profit organizations have significantly contributed to the understanding of oral contraceptives, promoting their use as a reliable method of preventing unwanted pregnancies.

Additionally, Modern lifestyles and changing demographics, including delayed childbirth and an increase in the number of working women, have driven the demand for convenient and effective contraceptive methods. Oral contraceptives offer an easy-to-use solution that fits into the busy lives of modern women.

Moreover, Government policies supporting family planning and reproductive health have also played a crucial role. Subsidies and healthcare initiatives that make contraceptives more affordable and accessible are significant drivers of market growth.

Scope of the Report:

• The report analyses the OC/LEP Market by Value (USD Billion).
• The report analyses the OC/LEP Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Netherlands, China, Japan, India).
• The report presents the analysis of OC/LEP Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the OC/LEP Market by Type (Combination Contraceptives Pills, Progestin-only Pills)
• The report analyses the OC/LEP Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, By Distribution Channel and By Drug Class.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Sanofi, Novartis, Pfizer, Bayer AG, Merck & Co., Inc., Teva Pharmaceuticals, Abbvie, Viatris, and Cipla.